Skip to main content
. Author manuscript; available in PMC: 2021 Jun 11.
Published in final edited form as: Eur J Nucl Med Mol Imaging. 2016 Mar 21;43(10):1784–1791. doi: 10.1007/s00259-016-3357-x

Table 2.

Numbers of lesions identified on 68Ga-DOTATATE, 18F-FDG, 18F-FDOPA and 18F-FDA PET/CT, and CT/MRI compared to lesions identified by the imaging comparator

Lesion location 68Ga-DOTATATE PET/CT 18F-FDG PET/CT 18F-FDOPA PET/CTa 18F-FDA PET/CTa CT/MRI
All compartments 450/461 226/461 181/242 160/206 376/461
Mediastinum 46/46 26/46 17/24 21/21 27/46
Lungs 89/94 52/94 52/53 26/38 89/94
Abdomen 74/74 42/74 30/41 35/38 57/74
Liver 42/48 6/48 11/13 9/13 45/48
Bone 199/199 100/199 71/111 69/96 158/199
a

Not all patients underwent PET/CT scans with these radiopharmaceuticals